6'-hydroxy-O-desmethylangolensin | 153409-52-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - α-甲基脱氧安息香黄酮
• 英文名称: 6'-hydroxy-O-desmethylangolensin
• 英文别名: 6-hydroxy-O-demethylangolensin；2-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one
• CAS: 153409-52-0
• 化学式: C₁₅H₁₄O₅
• 分子量: 274.273
• InChiKey: IEFUAUZFJJOQMC-UHFFFAOYSA-N

物化性质

• 沸点：
  494.1±14.0 °C(Predicted)
• 密度：
  1.423±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  98
• 氢给体数：
  4
• 氢受体数：
  5

ADMET

代谢

6'-羟基-O-去甲基雄烯醇是一种已知的人体代谢物，属于2-(4-羟基苯基)-1-(2,4,6-三羟基苯基)丙-2-烯-1-酮的代谢产物。

6'-Hydroxy-O-desmethylangolensin is a known human metabolite of 2-(4-Hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)prop-2-en-1-one.

来源:NORMAN Suspect List Exchange

反应信息

• 作为反应物：
  描述：

  丙酮醛 、 6'-hydroxy-O-desmethylangolensin 以 aq. phosphate buffer 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  Dietary Genistein Reduces Methylglyoxal and Advanced Glycation End Product Accumulation in Obese Mice Treated with High-Fat Diet

  摘要：

  Our previous study has found that dietary genistein could ameliorate high-fat diet (HFD)-induced obesity and especially lower methylglyoxal (MGO) and advanced glycation end product (AGE) accumulation in healthy mice exposed to genistein and HFD. However, it is still unclear whether dietary genistein intervention has a similar beneficial effect in obese mice. In this study, the mice were induced with obesity after being fed a HFD for nine weeks before being administered with two doses of genistein, 0.1% (G 0.1) and 0.2% (G 0.2), in the HFD for additional 19 weeks. After 19 week treatment, genistein supplementation reduced body and liver weights, plasma and liver MGO levels, and kidney AGE levels in mice. Mechanistically, genistein upregulated the expressions of glyoxalase I and II and aldose reductase to detoxify MGO, and genistein and its microbial metabolites, dihydrogenistein and 6'-hydroxy-O-demethylangolensin, were able to trap endogenous MGO via formation of MGO conjugates. Taken together, our results provide novel insights into the antiobesity and antiglycation roles of dietary genistein in obese subjects.

  DOI：

  10.1021/acs.jafc.0c03286
• 作为产物：
  描述：

  染料木素 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以47%的产率得到6'-hydroxy-O-desmethylangolensin
  参考文献：
  名称：

  Dietary Genistein Reduces Methylglyoxal and Advanced Glycation End Product Accumulation in Obese Mice Treated with High-Fat Diet

  摘要：

  Our previous study has found that dietary genistein could ameliorate high-fat diet (HFD)-induced obesity and especially lower methylglyoxal (MGO) and advanced glycation end product (AGE) accumulation in healthy mice exposed to genistein and HFD. However, it is still unclear whether dietary genistein intervention has a similar beneficial effect in obese mice. In this study, the mice were induced with obesity after being fed a HFD for nine weeks before being administered with two doses of genistein, 0.1% (G 0.1) and 0.2% (G 0.2), in the HFD for additional 19 weeks. After 19 week treatment, genistein supplementation reduced body and liver weights, plasma and liver MGO levels, and kidney AGE levels in mice. Mechanistically, genistein upregulated the expressions of glyoxalase I and II and aldose reductase to detoxify MGO, and genistein and its microbial metabolites, dihydrogenistein and 6'-hydroxy-O-demethylangolensin, were able to trap endogenous MGO via formation of MGO conjugates. Taken together, our results provide novel insights into the antiobesity and antiglycation roles of dietary genistein in obese subjects.

  DOI：

  10.1021/acs.jafc.0c03286

文献信息

• THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES
  申请人：KELLY Graham Edmund

  公开号：US20080287528A1

  公开（公告）日：2008-11-20

  Therapeutic methods of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (1), in which Z is H, R 1 is H, or R A CO where R A is C 1-10 alkyl or an amino acid, R 2 is H, OH, or OR B where R B is an amino acid, or COR A where R A is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c), or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (e), or W and A taken together with the groups with which they are associated comprise (f) and B is (g) wherein R 3 is H, COR A where R A is as previously defined, CO 2 R C where R C is C 1-10 alkyl, or COR B where R B is as previously defined, R 4 is H, COR D where R D is H, OH, C 1-10 alkyl or an amino acid, CO 2 R C where R C is as previously defined, COR E where R E is H, C 1-10 alkyl or an amino acid, COOH, COR C where R C is as previously defined, or CONHR E where R E is as previously defined, R 5 is H, CO 2 R C where R C is as previously defined, or COR C OR E where R C and R E are as previously defined, and where the two R 5 groups are attached to the same group they are the same or different, R 6 is H or hydroxy C 1-10 alkyl, X is preferably O, but may be N or S, and Y is (h) where R 7 is H, or C 1-10 alkyl.

  本文描述了治疗方法、组合物和食品，其中包含一般式（1）所描述的异黄酮化合物，其中Z为H，R1为H或RACO，其中RA为C1-10烷基或氨基酸，R2为H、OH或ORB，其中RB为氨基酸，或CORA，其中RA如先前定义，W为H，A为H或OH，B选自（a）、（b）、（c），或W为H，A和B结合形成六元环，选自（d），或W、A和B与它们相关的基团组成（e），或W和A与它们相关的基团组成（f），B为（g），其中R3为H，CORA，其中RA如先前定义，CO2RC，其中RC为C1-10烷基，或CORB，其中RB如先前定义，R4为H，CORD，其中RD为H、OH、C1-10烷基或氨基酸，或CO2RC，其中RC如先前定义，CORE，其中RE为H、C1-10烷基或氨基酸，或COOH，CORC，其中RC如先前定义，或CONHRE，其中RE如先前定义，R5为H，CO2RC，其中RC如先前定义，或CORCORE，其中RC和RE如先前定义，且当两个R5基团连接到同一基团时，它们相同或不同，R6为H或羟基C1-10烷基，X优选为O，但也可以为N或S，Y为（h），其中R7为H或C1-10烷基。
• US7202273B2
  申请人：——

  公开号：US7202273B2

  公开（公告）日：2007-04-10
• US7419998B2
  申请人：——

  公开号：US7419998B2

  公开（公告）日：2008-09-02
• US7915308B2
  申请人：——

  公开号：US7915308B2

  公开（公告）日：2011-03-29